Show simple item record

dc.contributor.authorTveit, Kåre Steinar
dc.contributor.authorDuvetorp, Albert
dc.contributor.authorØstergaard, Mikkel
dc.contributor.authorSkov, Lone
dc.contributor.authorDanielsen, Kjersti
dc.contributor.authorIversen, Lars F.
dc.contributor.authorSeifert, Oliver
dc.date.accessioned2019-05-20T09:17:19Z
dc.date.available2019-05-20T09:17:19Z
dc.date.issued2018-09-22
dc.description.abstract<i>Background</i>: There are scarce data in Scandinavia about treatment satisfaction among patients with psoriasis (PsO)and/or psoriatic arthritis (PsA). The number of patients receiving systemic treatment is unknown.<p> <p><i>Objective</i>: To describe patients’experience of treatments for PsO/PsA in Sweden, Denmark and Norway, addressing communication with physicians, satisfaction with treatment and concerns regarding treatment options.<p> <p><i>Methods</i>: The NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP) asked 22 050 adults (randomly selected from the YouGov panels in Sweden, Denmark and Norway) whether they had PsO/PsA. A total of 1264 individuals who reported physician-diagnosed PsO/PsA were invited to participate in the full survey; 96.6% responded positively.<p> <p><i>Results</i>: Systemic treatment use was reported by 14.6% (biologic: 8.1%) of respondents with PsO only and by 58.5% (biologic: 31.8%) of respondents with PsA. Biologic treatments were more frequently reported by respondents considering their disease severe (26.8% vs 6.7% non-severe) and those who were members of patient organizations (40.7% vs 6.9% non-members). Discussing systemic treatments with their physician was reported significantly more frequently by respondents with PsA, those perceiving their disease as severe (although 35.2% had never discussed systemic treatment with their physician) and those reporting being a member of a patient organization (P<0.05). Many respondents reported health risk concerns and dissatisfaction with their treatment. Of special interest was that respondents aged 45–75 years reported less experience with biologics (8.1%) than those aged 18–44 years (21.5%). The older respondents also reported more uncertainty regarding long-term health risks related to systemic treatments (most [66.7–72.9%] responded‘do not know’when asked about the risk of systemic options).<p> <p><i>Conclusion</i>: It appears likely that substantial numbers of Scandinavians suffering from severe PsO/PsA are not receiving optimal treatment from a patient perspective, particularly older patients. Also, one-third of respondents with severe symptoms had never discussed systemic treatment with a physician.<p>en_US
dc.description.sponsorshipCelgene Corporationen_US
dc.descriptionSource at <a href=https://doi.org/10.1111/jdv.15252>https://doi.org/10.1111/jdv.15252. </a>en_US
dc.identifier.citationTveit, K.S., Duvetorp, A., Østergaard, M., Skov, L., Danielsen, K., Iversen, L. & Seifert, O. (2018). Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). <i>Journal of the European Academy of Dermatology and Venereology, 33</i>(2), 340-354. https://doi.org/10.1111/jdv.15252en_US
dc.identifier.cristinIDFRIDAID 1680028
dc.identifier.doi10.1111/jdv.15252
dc.identifier.issn0926-9959
dc.identifier.issn1468-3083
dc.identifier.urihttps://hdl.handle.net/10037/15332
dc.language.isoengen_US
dc.publisherWileyen_US
dc.relation.journalJournal of the European Academy of Dermatology and Venereology
dc.rights.accessRightsopenAccessen_US
dc.titleTreatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP)en_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record